Nov 01, 2022 9:25am EDT Lexaria Receives Independent Review Board Approval for its Upcoming Human Oral Nicotine Study
Aug 11, 2022 8:30am EDT Lexaria Bioscience Corp. (NASDAQ: LEXX) Focused on Filling Need for Hypertension Treatment Solution
Aug 10, 2022 8:15am EDT Lexaria Announces Positive Feedback from Pre-IND Meeting with FDA on DehydraTECH-CBD for Hypertension
Aug 09, 2022 8:30am EDT Lexaria Bioscience Corp. (NASDAQ: LEXX) Developing Powerful Tech to Treat Hypertension
Jul 27, 2022 9:10am EDT Lexaria's DehydraTECH-CBD Hypertension Study HYPER-H21-4 Dosing Complete with No Serious Adverse Events
Jul 26, 2022 9:05am EDT Lexaria's Licensee Premier Wellness Science Co., Ltd. Launches New Brand in Preparation to Deploy DehydraTECH CBD Products in Japan
